A Three-month, Randomized, Parallel Active Control, Single and Repeat Dose, Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VAL-1221 Delivered Intravenously (IV) in Ambulatory and Vent
Clinical Trial Grant
Administered By
Pediatrics, Medical Genetics
Awarded By
Valerion Therapeutics, Inc
Start Date
April 11, 2017
End Date
March 31, 2020
Administered By
Pediatrics, Medical Genetics
Awarded By
Valerion Therapeutics, Inc
Start Date
April 11, 2017
End Date
March 31, 2020